UNS unilife corporation

i was wrong, page-8

  1. 10,292 Posts.
    lightbulb Created with Sketch. 21
    For some clarification
    I do not blame AS for me being wrong I always take full responsibility for my decisions I drew a conclusion based on the statement made at the time that the unknown pharma deal went through that a fee would be negotiated

    Exclusivity of Supply
    An exclusivity fee will be added onto the negotiated unit price of the Unifill syringe when agreed exclusivity conditions are met. Unilife will grant to the pharmaceutical customer an exclusivity of supply right for the Unifill syringe for a specific indication and Western European geography. from the press releas june 2012


    I combined that with the statement that sales would progressivley increase

    Projected Revenue
    Initial sales of the Unifill syringe to the pharmaceutical customer will commence in July 2012. Sales are expected to progressively increase in anticipation of the scheduled commercial launch of the pharmaceutical customer's drug within international geographies after regulatory approvals are granted during Fiscal Year 2013. Annual unit volumes for the Unifill syringe within the initial European geography are expected to reach up to 10 million units during the contract period, generating up to $15 million in revenue per year. same reference

    And then I unaided drew the conclusion that the unknown pharma would not want to stockpile to many syringes before they released them onto the market in say the second half of 2013 and at the same time would want to tie up other geographic areas before letting the world know that they had the unifill

    AS far as AS is concerned I fully agree with henrietta that the job he has done is exceptional I really doubt that there ate two many others who could do the same




 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.